4
Changes in Ownership
Bicara Therapeutics Inc. Filed Acc 0001628280-26-015421
Chief Financial Officer sold 16,518 shares at an average $18.22 ($300,971)
- Chief Financial Officer acquired 16,518 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Hyep Ivan Chief Financial Officer | 2026-03-03 | Option exercise 10b5-1 | +7,318 | $3.79 | $27,734 | 152,673 | D |
| Hyep Ivan Chief Financial Officer | 2026-03-03 | Option exercise 10b5-1 | +6,237 | $3.79 | $23,637 | 158,910 | D |
| Hyep Ivan Chief Financial Officer | 2026-03-03 | Sale 10b5-1 | −13,555 | $18.22 | $246,910 | 145,355 | D |
| Hyep Ivan Chief Financial Officer | 2026-03-04 | Option exercise 10b5-1 | +2,963 | $3.79 | $11,229 | 148,318 | D |
| Hyep Ivan Chief Financial Officer | 2026-03-04 | Sale 10b5-1 | −2,963 | $18.25 | $54,062 | 145,355 | D |
| Derivatives | |||||||
| Hyep Ivan Chief Financial Officer | 2026-03-03 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,318 | 58,144 | D | ||
| Hyep Ivan Chief Financial Officer | 2026-03-03 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,237 | 82,747 | D | ||
| Hyep Ivan Chief Financial Officer | 2026-03-04 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,963 | 79,784 | D | ||
| Open-market sales · 16,518 sh · avg $18.22 · $300,971 | |||||||
Loading xslF345X05/wk-form4_1772755729.xml…